Monte Rosa Therapeutics (NASDAQ: GLUE) is a clinical-stage biopharmaceutical company that discovers and develops molecular glue degrader drug candidates. Revenue comes from licensing and collaboration agreements with pharmaceutical partners, not from commercial product sales. As of the 10-K filed March 17, 2026, revenues have consisted primarily of consideration from the Roche Agreement, the 2024 Novartis License Agreement, and the 2025 Novartis License Agreement. The company has no approved products and operates as a pre-commercial drug discovery and development organization. Its QuEEN drug discovery engine, which incorporates AI, underpins its molecular glue degrader platform. Operations span two locations: a primary site and an office and laboratory space of 44,685 square feet in Basel-City, Switzerland, with the lease extended through June 2027. CEO Markus Warmuth, M.D. serves as both President and Principal Executive Officer as of March 17, 2026.

Revenue model

Licensing and collaboration agreements, specifically the Roche Agreement, the 2024 Novartis License Agreement, and the 2025 Novartis License Agreement, recognized under ASC 606 as performance obligations are satisfied. No commercial product revenue as of the filing date.

Products and services

Molecular glue degrader drug candidates; QuEEN drug discovery engine incorporating AI for drug discovery.

Customers and end markets

Pharmaceutical partners Roche and Novartis, as named in the 10-K filed March 17, 2026. End market is targeted protein degradation therapeutics.

Value-chain role

Drug discovery and early-stage clinical development; licenses technology and candidates to large pharmaceutical companies.

Geographic exposure

United States (primary operations) and Basel-City, Switzerland (44,685 square feet office and laboratory space, lease through June 2027).

Source: SEC 10-K, filed 2026-03-17

Industry: Biological Products, (No Diagnostic Substances) Peers: Invivyd Inc ALBIREO PHARMA, INC. Humacyte Inc Anika Therapeutics Inc Arcturus Therapeutics Holdings Inc EAGLE PHARMACEUTICALS, INC. Karyopharm Therapeutics Inc MeiraGTx Holdings PLC Scholar Rock Holding Corp